Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

TTNS in SCI Patients With Neurogenic Detrusor Overactivity

20 augusti 2026 uppdaterad av: National University Hospital, Singapore

Pilot Study to Evaluate the Effectiveness and Tolerability of Transcutaneous Tibial Nerve Stimulation (TTNS) in Management of Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injuries.

This is a prospective, single-arm, pilot study to assess effectiveness and tolerability of transcutaneous tibial nerve stimulation (TTNS) in managing neurogenic detrusor overactivity in spinal cord injury patients. 12 - 16 spinal cord injury patients with neurogenic detrusor overactivity will be recruited. The intervention includes administration of TTNS at the highest tolerated level for 20 minutes daily for 4 weeks, using a neuromodulation device -- Tensi+.

Outcome measures including Urodynamic Study (UDS) will be retrieved or collected at baseline and collected after the 4 weeks of TTNS administration. Other outcome measures include Overactive Bladder Questionnaire Short Form (OAB-Q-SF), which will be administered before and after TTNS administration, subject's level of discomfort and any adverse events experienced by the subject will be recorded after each intervention session and a bladder diary will be recorded weekly for subjects not on indwelling urinary catheters. A TTNS satisfaction survey will also be performed at the end of the study.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This study aims to evaluate the effectiveness and tolerability of TTNS in spinal cord injury patients with Neurogenic Detrusor Overactivity (NDO): a cohort of population where NDO is more prevalent but there are insufficient research and studies to look into different stimulation protocols and parameters to achieve more sustainable and longer lasting effects in patients with spinal cord injuries.

This is a prospective single-arm pilot study in spinal cord injury patients with neurogenic detrusor overactivity. Suitable subjects will be seen at the wards during their inpatient stay and will be enrolled into the study if they meet the study inclusion criteria, have no contraindication urodynamic study and are able to give informed consent.

The TTNS will be administered to subjects at the highest tolerated level for 20 minutes daily for 4 weeks. The TTNS will be administered using a neuromodulation device - Tensi+. It is a wearable device consisting of a longitudinal piece with two silicone graphite electrodes that can be strapped on the patient's ankle after application of a conductor gel. The device has a single power button to turn on/off the device and another button to adjust the level of neurostimulation, as tolerated. It has an in-built safety mechanism that will be automatically activated to limit the maximum current delivered to 50mA, at any level of intensity chosen.

Outcome measures include Urodynamic Study which will be collected at baseline (Week 0, before starting TTNS stimulations) and after the end of TTNS simulations (Week 5, after completing all TTNS stimulations). Other outcome measures include Overactive Bladder Questionnaire Short Form (OAB-Q-SF), which will be administered before (Week 0) and after TTNS administration (Week 5), subject's level of discomfort and any adverse events experienced by the subject will be recorded after each intervention session (Weeks 1-4) and a bladder diary will be recorded weekly for subjects not on indwelling urinary catheters (Weeks 1-4). A TTNS satisfaction survey will also be performed at the end of the study (Week 5).

Studietyp

Interventionell

Inskrivning (Beräknad)

12

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Aged between 21 years and 70 years old
  2. Clinical diagnosis of spinal cord injury
  3. Diagnosis of neurogenic detrusor overactivity
  4. Able to tolerate Urodynamic study
  5. Ability to provide informed consent

Exclusion Criteria:

  1. Patients with active implantable device or ankle orthopaedic implant, Ankle articular diseases.
  2. Pacemakers or implanted electrical devices, including deep brain stimulation.
  3. Ulceration or broken skin in area of TTNS device placement.
  4. Patients with BPH: predominantly voiding Lower Urinary Tract Symptoms (LUTS), Uroflow demonstrating obstructive pattern
  5. Active urinary tract infection
  6. Pregnancy
  7. Known bladder tumour, urinary calculi
  8. Predominant stress urinary incontinence
  9. Prior treatment with transcutaneous PTNS or percutaneous PTNS (any time), sacral neuromodulation (anytime) or intradetrusor botulinum toxin injection within the past 6 months
  10. Past medical history of psychiatric conditions
  11. Patients with spinal shock
  12. Patients with lower motor neuron syndrome

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: transcutaneous tibial nerve stimulation
28 sessions of transcutaneous tibial nerve stimulation (TTNS) in 4 weeks
Enhet: TTNS
Participants will undergo 28 sessions of TTNS in 4 weeks. TTNS will be administered using a neuromodulation device - Tensi+.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Maximum Cystometric Capacity (MCC)
Tidsram: Week 0
Measured by Urodynamic Studies (UDS). MCC is the maximum volume of fluid the bladder can hold during filling cystometry, measured in millilitres (mL). It represents the point at which the patient feels a strong urge to void, or when the clinician decides to stop filling due to safety concerns (e.g., high pressure, leakage, or autonomic dysreflexia).
Week 0
Maximum Cystometric Capacity (MCC)
Tidsram: Week 5
Measured by Urodynamic Studies (UDS). MCC is the maximum volume of fluid the bladder can hold during filling cystometry, measured in millilitres (mL). It represents the point at which the patient feels a strong urge to void, or when the clinician decides to stop filling due to safety concerns (e.g., high pressure, leakage, or autonomic dysreflexia).
Week 5
Detrusor Leak Point Pressure (DLPP)
Tidsram: Week 0
Measured by Urodynamic Studies (UDS). DLPP is the detrusor pressure at which urine leaks past the outlet without any abdominal straining or detrusor contraction. It reflects the risk of upper urinary tract damage.
Week 0
Detrusor Leak Point Pressure (DLPP)
Tidsram: Week 5
Measured by Urodynamic Studies (UDS). DLPP is the detrusor pressure at which urine leaks past the outlet without any abdominal straining or detrusor contraction. It reflects the risk of upper urinary tract damage.
Week 5

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overactive Bladder Questionnaire Short Form (OAB-Q SF)
Tidsram: Week 0
OAB-Q SF is a patient-reported outcome measure to assess both the severity of overactive bladder symptoms and their impact on health-related quality of life. It consists of two components: a 6-item Symptom Bother scale (urgency, frequency, nocturia and urge incontinence) and a 13-item Health-Related Quality of Life scale (coping, concern, sleep and social interaction). Higher symptom scores reflect greater severity and higher Health-Related Quality of Life scores reflect better well-being.
Week 0
Overactive Bladder Questionnaire Short Form (OAB-Q SF)
Tidsram: Week 5
OAB-Q SF is a patient-reported outcome measure to assess both the severity of overactive bladder symptoms and their impact on health-related quality of life. It consists of two components: a 6-item Symptom Bother scale (urgency, frequency, nocturia and urge incontinence) and a 13-item Health-Related Quality of Life scale (coping, concern, sleep and social interaction). Higher symptom scores reflect greater severity and higher Health-Related Quality of Life scores reflect better well-being.
Week 5
Post-TTNS survey
Tidsram: Week 5
The Post-TTNS survey is a short questionnaire designed to gather feedback from subjects after completing the course of tibial nerve stimulaton. It assesses subject-reported outcomes such as tolerability, comfort during the stimulation, ease of use, satisfaction with the procedure, perceived changes in urinary symptoms and subject's overall experience.
Week 5
Bladder Diary
Tidsram: Week 1
For subjects not on indwelling urinary catheters (IDC), subjects and study team will keep and record a bladder diary weekly. A bladder diary is used to record daily urinary habits, providing an objective record of the subject's bladder function to assess urinary symptoms.
Week 1
Bladder Diary
Tidsram: Week 2
For subjects not on indwelling urinary catheters (IDC), subjects and study team will keep and record a bladder diary weekly. A bladder diary is used to record daily urinary habits, providing an objective record of the subject's bladder function to assess urinary symptoms.
Week 2
Bladder Diary
Tidsram: Week 3
For subjects not on indwelling urinary catheters (IDC), subjects and study team will keep and record a bladder diary weekly. A bladder diary is used to record daily urinary habits, providing an objective record of the subject's bladder function to assess urinary symptoms.
Week 3
Bladder Diary
Tidsram: Week 4
For subjects not on indwelling urinary catheters (IDC), subjects and study team will keep and record a bladder diary weekly. A bladder diary is used to record daily urinary habits, providing an objective record of the subject's bladder function to assess urinary symptoms.
Week 4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

National University Hospital, Singapore

Utredare

  • Huvudutredare: Gobinathan Chandran, MBBS, National University Hospital, Singapore

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

31 december 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

19 februari 2026

Först inskickad som uppfyllde QC-kriterierna

20 augusti 2026

Första postat (Faktisk)

25 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 augusti 2026

Senast verifierad

1 september 2025

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 2025/0862

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera